Inhibition of leukotrienes and their potential role in type 1 diabetes pathogenesis: implications for montelukast as a therapeutic agent: a case report.
- DOI
- 10.3389/fcdhc.2024.1494470
- Published
- 2024
- Container
- Frontiers in clinical diabetes and healthcare
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3389/fcdhc.2024.1494470,
title = {Inhibition of leukotrienes and their potential role in type 1 diabetes pathogenesis: implications for montelukast as a therapeutic agent: a case report.},
author = {Fatulla P and Ström I and Lingblom C and Lind M},
year = {2024},
journal = {Frontiers in clinical diabetes and healthcare},
doi = {10.3389/fcdhc.2024.1494470},
url = {https://doi.org/10.3389/fcdhc.2024.1494470}
}RIS
TY - JOUR TI - Inhibition of leukotrienes and their potential role in type 1 diabetes pathogenesis: implications for montelukast as a therapeutic agent: a case report. AU - Fatulla P AU - Ström I AU - Lingblom C AU - Lind M PY - 2024 JO - Frontiers in clinical diabetes and healthcare DO - 10.3389/fcdhc.2024.1494470 UR - https://doi.org/10.3389/fcdhc.2024.1494470 ER -
APA
P, F., I, S., C, L., & M, L. (2024). Inhibition of leukotrienes and their potential role in type 1 diabetes pathogenesis: implications for montelukast as a therapeutic agent: a case report.. Frontiers in clinical diabetes and healthcare. https://doi.org/10.3389/fcdhc.2024.1494470
Source records
- pubmed · retrieved 2026-09-25T18:31:46.447Z